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Until relatively recently, the polyene antibiotics, particularly nystatin, amphotericin Band natamycin have been the drugs of choice for the treatment of candida infections. These polyenes are macrolide antibiotics produced mainly by Streptomyces species. They interact with the membranes of sensitive organisms causing leakage of internal constituents and ultimately cell death.
Nystatin is very effective for topical treatment and there are virtually no side effects related to its use. Amphotericin B, unlike either nystatin or natamycin, may be used not only topically but can also be given by the intravenous route. Neither primary resistance nor the development of laboratory demonstrable resistant strains of yeasts during therapy has presented problems during the often prolonged use of these polyene antibiotics.
. In recent years, the realization of the antifungal properties of imidazole derivatives has produced three compounds, clotrimazole, miconazole and econazole, which are not only effective against candida and other yeasts, but also against other fungus species pathogenic to man.
Clotrimazole is a tritylimidazole derivative which acts on the cell membrane of fungi and inhibits protein synthesis. The drug is very active in vitro against C. albicans and clinical trials have established that it is as effective as the polyenes when applied to the skin or mucosal surfaces (Clayton & Connor 1973) . Miconazole, a phenethalcohol imidazole derivative, has a similar spectrum of activity to clotrimazole and is as effective as clotrimazole when applied topically to treat fungal infections of the skin and mucous membranes (Clayton & Knight 1976) . It may also be administered orally or intravenously. There are, as yet, comparatively few reports in the literature on the treatment of systemic candida infections by oral or intravenous miconazole and its value has still to be established.
The presence of primary resistance or the development of resistance to imidazoles during treatment has not been a therapeutic problem. Recently, however, Holt & Azmi (1978) o141-fJ768/79/120929-fJ2/$01.OO/0 reported the emergence of resistance to miconazole of C. albieans during prolonged therapy for urinary candidiasis; the strain was found to be similarly resistant to clotrimazole and econazole.
The occurrence of resistance is much more frequently encountered with another anticandida agent, S-fluorocytosine. Primary resistance present in strains which have never been exposed to the drug has been reported in as many as 12% of C. albicans strains isolated from clinical material (Hamilton-Miller 1972) , and the emergence of resistant strains during treatment has been a cause of therapeutic failure. S-fluorocytosine is a halogenated pyrimidine which is well absorbed when given orally and is relatively nontoxic for man since it is not metabolized but is excreted unchanged in the urine. Fungi, such as candida species, which have a permease to allow its entry and deaminases to convert it to S-fluorouracil, are highly sensitive to its action. Topical use of S-fluorocytosine is contraindicated because of the likelihood of inducing resistance.
Since more than one antifungal drug is now available that can be used systemically, combined therapy for fungal infections becomes a possibility. A synergistic potential has been shown to exist between amphotericin Band S-fluorocytosine in vitro (Medoff et al. 1971) . Amphotericin B, by its action on the fungal cytoplasmic membrane, apparently enhances the penetration of other agents, such as S-fluorocytosine, into the cells rendering them more susceptible to the drug. The clinical value of this apparent synergy has still to be evaluated.
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Any factor which compromises cell-mediated immunity will favour the emergence of Candida albicans as a chronic pathogen. Thus, treatment with corticosteroids or cytotoxic drugs, malnourishment, iron deficiency and endocrinopathy (particularly defects of calcium metabolism) may predispose some patients to chronic candidiasis. Patients with inadequate numbers of circulating lymphocytes or phagocytes, as well as those with poor phagocyte function, are also at risk. Some authorities therefore reserve the diagnosis of chronic mucocutaneous candidiasis (CMC) for those patients with chronic candidiasis in whom the above predisposing factors have been excluded (J R Hobbs, 1978, personal communication) .
In vivo tests
Patients with CMC fail to produce an effective immune response to candida. Immunological investigation aims at pin-pointing this defect. Cell-mediated immunity (CMI) is classically assessed in vivo by observing at 48 hours the inflammatory response to intradermal challenge. The continuing problem has been to make the challenge realistic. Unfortunately, commercially available preparations of candida extract allow IS-20% nonresponders amongst normals who could be expected to possess specific CMI against candida. Some centres, therefore, produce their own extract and claim fewer nonresponding normals (J R Hobbs, 1978, personal communication) .
Most patients with CMC, as expected, show no response to intradermal challenge. However, a few do respond, raising intriguing immunological questions yet to be resolved.
